Literature DB >> 7907913

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

L M Mulligan1, C Eng, C S Healey, D Clayton, J B Kwok, E Gardner, M A Ponder, A Frilling, C E Jackson, H Lehnert.   

Abstract

We have analysed 118 families with inherited medullary thyroid carcinoma (MTC) for mutations of the RET proto-oncogene. These included cases of multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B) and familial MTC (FMTC). Mutations at one of 5 cysteines in the extracellular domain were found in 97% of patients with MEN 2A and 86% with FMTC but not in MEN 2B patients or normal controls. 84% of the MEN2A mutations affected codon 634. MEN 2A patients with a Cys634 to Arg substitution had a greater risk of developing parathyroid disease than those with other codon 634 mutations. Our data show a strong correlation between disease phenotype and the nature and position of the RET mutation, suggesting that a simple, constitutive activation of the RET tyrosine kinase is unlikely to explain the events leading to MEN 2A and FMTC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907913     DOI: 10.1038/ng0194-70

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  116 in total

Review 1.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Sympathoadrenal hyperplasia causes renal malformations in Ret(MEN2B)-transgenic mice.

Authors:  C Gestblom; D A Sweetser; B Doggett; R P Kapur
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2.

Authors:  V Neocleous; N Skordis; G Portides; E Efstathiou; C Costi; N Ioannou; M Pantzaris; V Anastasiadou; C Deltas; L A Phylactou
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

4.  Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.

Authors:  Syed A Ahmed; Karen Snow-Bailey; W Edward Highsmith; Weimin Sun; Raymond G Fenwick; Rong Mao
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

5.  RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis.

Authors:  Rebecca L Margraf; Rong Mao; W Edward Highsmith; Leonard M Holtegaard; Carl T Wittwer
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

Review 6.  Surgical management of medullary thyroid carcinoma.

Authors:  Agathoklis Konstantinidis; Michael Stang; Sanziana A Roman; Julie Ann Sosa
Journal:  Updates Surg       Date:  2017-04-13

7.  Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up.

Authors:  J A Olson; M K DeBenedetti; D S Baumann; S A Wells
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

8.  Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region.

Authors:  M Schutte; L T da Costa; S A Hahn; C Moskaluk; A T Hoque; E Rozenblum; C L Weinstein; M Bittner; P S Meltzer; J M Trent
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

9.  Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families.

Authors:  M Rossel; I Schuffenecker; M Schlumberger; C Bonnardel; E Modigliani; P Gardet; J Navarro; Y Luo; G Romeo; G Lenoir
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

10.  Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect.

Authors:  H Brauch; T Kishida; D Glavac; F Chen; F Pausch; H Höfler; F Latif; M I Lerman; B Zbar; H P Neumann
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.